Summary
Published in Molecular Cancer in 2025, this review paper by Li and colleagues examines the tailoring of traditional Chinese medicine within cancer therapy contexts. It likely synthesises evidence on how specific TCM constituents or formulations may be matched to cancer subtypes, molecular profiles, or treatment stages to optimise therapeutic efficacy. The paper probably discusses mechanisms of action, potential synergies with chemotherapy or immunotherapy, and emerging evidence for personalised TCM approaches in oncology.
UK applicability
TCM is not a mainstream component of NHS cancer care, so direct clinical applicability in the UK is limited; however, findings regarding bioactive plant compounds and their molecular mechanisms may be of interest to UK researchers exploring integrative oncology or phytochemical-based therapeutics.
Key measures
Likely includes assessment of TCM compound bioactivity, molecular targets, clinical response indicators, and integration with standard oncological therapies; specific quantitative metrics uncertain from title alone
Outcomes reported
The paper likely examines how traditional Chinese medicine (TCM) formulations and compounds can be tailored or personalised to enhance cancer therapy outcomes, possibly addressing tumour heterogeneity, drug resistance, or synergy with conventional treatments.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.